Pfizer's Prevnar 13 Could Gain Edge With Vaccine Panel Review
Executive Summary
An endorsement from FDA's Vaccines and Related Biological Products Advisory Committee for Wyeth's (now Pfizer's) Prevnar 13 would be a positive step for the firm in its race against GlaxoSmithKline rival vaccine Synflorix to capture the next-generation pneumococcal vaccine market